DK3925952T3 - Prostataspecifik membranantigen-målrettede højaffinitetsmidler til endoradioterapi af prostatacancer / Prostate-Specific Membrane Antigen Targeted High-Affinity Agents For Endoradiotherapy Of Prostate Cancer - Google Patents
Prostataspecifik membranantigen-målrettede højaffinitetsmidler til endoradioterapi af prostatacancer / Prostate-Specific Membrane Antigen Targeted High-Affinity Agents For Endoradiotherapy Of Prostate Cancer Download PDFInfo
- Publication number
- DK3925952T3 DK3925952T3 DK21177643.0T DK21177643T DK3925952T3 DK 3925952 T3 DK3925952 T3 DK 3925952T3 DK 21177643 T DK21177643 T DK 21177643T DK 3925952 T3 DK3925952 T3 DK 3925952T3
- Authority
- DK
- Denmark
- Prior art keywords
- prostate
- endoradiotherapy
- specific membrane
- membrane antigen
- affinity agents
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
- C07C275/06—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton
- C07C275/16—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton being further substituted by carboxyl groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/004—Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Optics & Photonics (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662311697P | 2016-03-22 | 2016-03-22 | |
| EP17771028.2A EP3433238B1 (en) | 2016-03-22 | 2017-03-22 | Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3925952T3 true DK3925952T3 (da) | 2024-02-05 |
Family
ID=59899817
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK21177643.0T DK3925952T3 (da) | 2016-03-22 | 2017-03-22 | Prostataspecifik membranantigen-målrettede højaffinitetsmidler til endoradioterapi af prostatacancer / Prostate-Specific Membrane Antigen Targeted High-Affinity Agents For Endoradiotherapy Of Prostate Cancer |
| DK17771028.2T DK3433238T3 (da) | 2016-03-22 | 2017-03-22 | Højaffinitetsmidler målrettet prostataspecifikt membranantigen til endoradioterapi af prostatacancer |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17771028.2T DK3433238T3 (da) | 2016-03-22 | 2017-03-22 | Højaffinitetsmidler målrettet prostataspecifikt membranantigen til endoradioterapi af prostatacancer |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US11458213B2 (https=) |
| EP (3) | EP4385981A1 (https=) |
| JP (4) | JP7073270B2 (https=) |
| KR (4) | KR20220063298A (https=) |
| CN (3) | CN120172884A (https=) |
| AU (1) | AU2017238181B2 (https=) |
| BR (1) | BR112018069507A2 (https=) |
| CA (1) | CA3018709A1 (https=) |
| CL (1) | CL2018002683A1 (https=) |
| CY (1) | CY1124487T1 (https=) |
| DK (2) | DK3925952T3 (https=) |
| ES (2) | ES2972148T3 (https=) |
| FI (1) | FI3925952T3 (https=) |
| HR (2) | HRP20240215T1 (https=) |
| HU (2) | HUE065327T2 (https=) |
| LT (2) | LT3925952T (https=) |
| MX (1) | MX384823B (https=) |
| PH (1) | PH12018502048A1 (https=) |
| PL (2) | PL3925952T3 (https=) |
| PT (2) | PT3433238T (https=) |
| RS (2) | RS62274B1 (https=) |
| RU (2) | RU2021115958A (https=) |
| SA (1) | SA518400103B1 (https=) |
| SI (2) | SI3925952T1 (https=) |
| TR (1) | TR201813644T1 (https=) |
| WO (1) | WO2017165473A1 (https=) |
| ZA (1) | ZA201806389B (https=) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112019002560B1 (pt) | 2016-08-10 | 2022-08-16 | Cancer Targeted Technology Llc | Composto, composição farmacêutica, seus usos e método de preparação do mesmo |
| EP3544960A1 (en) * | 2016-11-23 | 2019-10-02 | Cancer Targeted Technology LLC | Albumin-binding psma inhibitors |
| CN116474108A (zh) | 2016-12-14 | 2023-07-25 | 普渡研究基金会 | 成纤维细胞活化蛋白(fap)-靶向成像和治疗 |
| WO2018204477A1 (en) | 2017-05-02 | 2018-11-08 | Cornell University | Methods and reagents for tumor targeting with greater efficacy and less toxicity |
| WO2018222778A1 (en) * | 2017-05-30 | 2018-12-06 | The Johns Hopkins University | Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer |
| EP3494998A1 (en) * | 2017-12-11 | 2019-06-12 | Technische Universität München | Glycosylated psma inhibitors for imaging and endoradiotherapy |
| BR112020011727A2 (pt) * | 2017-12-11 | 2020-11-17 | Technische Universität München | ligantes de psma para imageamento e endorradioterapia |
| EP3494999A1 (en) * | 2017-12-11 | 2019-06-12 | Technische Universität München | Psma ligands for imaging and endoradiotherapy |
| SG11202005511VA (en) * | 2017-12-13 | 2020-07-29 | Sciencons AS | Complex comprising a psma-targeting compound linked to a lead or thorium radionuclide |
| SG11202007180QA (en) * | 2018-02-06 | 2020-08-28 | Univ Heidelberg | Fap inhibitor |
| KR20250126870A (ko) * | 2018-02-06 | 2025-08-25 | 더 존스 홉킨스 유니버시티 | 암 방사선 치료를 위한 psma 표적 방사성 할로겐화 우레아-폴리아미노카복실레이트 |
| JP7094591B2 (ja) * | 2018-03-30 | 2022-07-04 | フューチャーケム カンパニー リミテッド | 前立腺がんを診断および処置するためのｐｓｍａ標的放射性医薬品 |
| ES3034597T3 (en) * | 2018-04-27 | 2025-08-20 | Univ Iowa Res Found | Compositions for chelating metals at low temperatures |
| WO2020065045A1 (en) * | 2018-09-28 | 2020-04-02 | Universität Heidelberg | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of psma-expressing cancers |
| RU2697519C1 (ru) * | 2018-10-15 | 2019-08-15 | Общество с ограниченной ответственностью "Изварино Фарма" | Средство пептидной природы, включающее псма-связывающий лиганд на основе производного мочевины, способ его получения и применение для получения конъюгата с лекарственным и диагностическим агентом |
| KR102403970B1 (ko) * | 2018-12-27 | 2022-05-31 | (주)퓨쳐켐 | 카르복시산이 도입된 psma-표적 화합물 및 그의 용도 |
| CN120441497A (zh) * | 2019-07-02 | 2025-08-08 | 先进加速器应用意大利公司 | 前列腺特异性膜抗原（psma）配体及其用途 |
| WO2021001362A1 (en) | 2019-07-02 | 2021-01-07 | Advanced Accelerator Applications (Italy) Srl | Prostate specific membrane antigen (psma) ligands and uses thereof |
| RU2713151C1 (ru) * | 2019-07-02 | 2020-02-04 | Общество с ограниченной ответственностью "Изварино Фарма" | Конъюгат флуоресцентного красителя с веществом пептидной природы, включающим псма-связывающий лиганд на основе производного мочевины для визуализации клеток, экспрессирующих псма, способ его получения и применения |
| RU2730507C1 (ru) * | 2019-08-27 | 2020-08-24 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) | Соединение для диагностики опухолей, экспрессирующих псма, и композиция на его основе |
| CA3176404A1 (en) * | 2020-04-24 | 2021-10-28 | Ebrahim S. Delpassand | Composition, kit and method for diagnosis and treatment of prostate cancer |
| US20230330278A1 (en) * | 2020-04-29 | 2023-10-19 | Novartis Ag | Methods for radiolabelling psma binding ligands and their kits |
| US20230338587A1 (en) | 2020-08-31 | 2023-10-26 | Advanced Accelerator Applications International Sa | Method of treating psma-expressing cancers |
| WO2022043556A1 (en) | 2020-08-31 | 2022-03-03 | Novartis Ag | Stable radiopharmaceutical composition |
| US20230321285A1 (en) | 2020-08-31 | 2023-10-12 | Advanced Accelerator Applications International Sa | Method of treating psma-expressing cancers |
| EP4244216A1 (en) | 2020-11-12 | 2023-09-20 | ABX Advanced Biochemical Compounds GmbH | Ligands of prostate specific membrane antigen (psma) containing heteroaromatic linker building blocks |
| JP2023550411A (ja) * | 2020-11-19 | 2023-12-01 | ノバルティス アーゲー | 前立腺特異的膜抗原（ｐｓｍａ）リガンドの合成 |
| MX2021005089A (es) * | 2021-04-30 | 2022-11-01 | Instituto Nac De Investigaciones Nucleares | Radiofarmacos basados en el acido ((r)-1-((6-hidrazinilnicotinoil) d-alanil)pirrolidin-2-il)boronico (hynic-ifap) para la deteccion de la sobreexpresion de la proteina de activacion de fibrolastos. |
| KR20240022616A (ko) * | 2021-06-17 | 2024-02-20 | 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 | 복수의 킬레이트제와 생물학적 제제를 조합하기 위한 방법 및 재료 |
| KR20230050552A (ko) * | 2021-10-07 | 2023-04-17 | (주)퓨쳐켐 | 가돌리늄 화합물 및 이를 포함하는 전립선암의 진단 및 치료용 약학적 조성물 |
| EP4475900A1 (en) | 2022-02-09 | 2024-12-18 | Novartis AG | Pharmaceutical compositions comprising a 225-actinium-labelled complex and a bismuth sequestering agent |
| CN120826245A (zh) * | 2022-12-21 | 2025-10-21 | 梅约医学教育与研究基金会 | 将生物制剂与多种螯合剂组合的方法和材料 |
| KR20260040237A (ko) | 2023-07-21 | 2026-03-24 | 노파르티스 아게 | Psma 표적 방사성 리간드 치료 요법 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2926573C (en) * | 2007-06-26 | 2018-08-28 | The Johns Hopkins University | Labeled inhibitors of prostate specific membrane antigen (psma), biological evaluation, and use as imaging agents |
| WO2009070302A1 (en) | 2007-11-30 | 2009-06-04 | The Johns Hopkins University | Prostate specific membrane antigen (psma) targeted nanoparticles for therapy of prostate cancer |
| TW201034691A (en) * | 2008-12-05 | 2010-10-01 | Molecular Insight Pharm Inc | Technetium-and rhenium-bis(heteroaryl) complexes and methods of use thereof |
| EP3222617B1 (en) | 2009-03-19 | 2022-07-06 | The Johns Hopkins University | Psma-targeting compounds and uses thereof |
| WO2013022797A1 (en) * | 2011-08-05 | 2013-02-14 | Molecular Insight Pharmaceuticals | Radiolabeled prostate specific membrane antigen inhibitors |
| CN113149921B (zh) * | 2011-11-30 | 2024-11-29 | 约翰霍普金斯大学 | 前列腺特异性膜抗原(psma)的同源多价抑制剂和异源多价抑制剂以及其用途 |
| EP3300746B1 (en) * | 2013-01-14 | 2019-05-15 | Molecular Insight Pharmaceuticals, Inc. | Triazine based radiopharmaceuticals and radioimaging agents |
| EP2862857A1 (en) * | 2013-10-18 | 2015-04-22 | Deutsches Krebsforschungszentrum | Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
| LT4095130T (lt) | 2013-10-18 | 2024-04-25 | Novartis Ag | Žymėti prostatos specifinio membranos antigeno (psma) inhibitoriai, jų naudojimas kaip vizualizavimo medžiagų ir farmacinių medžiagų prostatos vėžiui gydyti |
| AU2015256002B2 (en) * | 2014-05-06 | 2020-01-02 | Northwestern University | Metal/radiometal-labeled PSMA inhibitors for PSMA-targeted imaging and radiotherapy |
| EP3183236B1 (en) | 2014-08-24 | 2022-04-20 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften | Method for the production of 18f-labeled active esters and their application exemplified by the preparation of a psma-specific pet-tracer |
| US11420910B2 (en) * | 2014-10-30 | 2022-08-23 | Katholieke Universitet Leuven | Methods for low temperature fluorine-18 radiolabeling of biomolecules |
| US11520472B2 (en) * | 2015-09-24 | 2022-12-06 | Mitutoyo Corporation | Inspection program editing environment including integrated alignment program planning and editing features |
| US10688200B2 (en) * | 2015-12-31 | 2020-06-23 | Five Eleven Pharma Inc. | Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy |
-
2017
- 2017-03-22 HR HRP20240215TT patent/HRP20240215T1/hr unknown
- 2017-03-22 DK DK21177643.0T patent/DK3925952T3/da active
- 2017-03-22 US US16/087,395 patent/US11458213B2/en active Active
- 2017-03-22 SI SI201731477T patent/SI3925952T1/sl unknown
- 2017-03-22 FI FIEP21177643.0T patent/FI3925952T3/fi active
- 2017-03-22 CN CN202510305793.6A patent/CN120172884A/zh active Pending
- 2017-03-22 RU RU2021115958A patent/RU2021115958A/ru unknown
- 2017-03-22 KR KR1020227015010A patent/KR20220063298A/ko not_active Ceased
- 2017-03-22 RS RS20211071A patent/RS62274B1/sr unknown
- 2017-03-22 CA CA3018709A patent/CA3018709A1/en active Pending
- 2017-03-22 EP EP24153551.7A patent/EP4385981A1/en active Pending
- 2017-03-22 PT PT177710282T patent/PT3433238T/pt unknown
- 2017-03-22 HU HUE21177643A patent/HUE065327T2/hu unknown
- 2017-03-22 KR KR1020187030310A patent/KR102396307B1/ko active Active
- 2017-03-22 LT LTEP21177643.0T patent/LT3925952T/lt unknown
- 2017-03-22 KR KR1020257012794A patent/KR20250057132A/ko active Pending
- 2017-03-22 RU RU2018133693A patent/RU2749399C2/ru active
- 2017-03-22 JP JP2018549808A patent/JP7073270B2/ja active Active
- 2017-03-22 LT LTEPPCT/US2017/023508T patent/LT3433238T/lt unknown
- 2017-03-22 RS RS20240205A patent/RS65188B1/sr unknown
- 2017-03-22 SI SI201730908T patent/SI3433238T1/sl unknown
- 2017-03-22 PL PL21177643.0T patent/PL3925952T3/pl unknown
- 2017-03-22 EP EP21177643.0A patent/EP3925952B1/en active Active
- 2017-03-22 PT PT211776430T patent/PT3925952T/pt unknown
- 2017-03-22 DK DK17771028.2T patent/DK3433238T3/da active
- 2017-03-22 PL PL17771028T patent/PL3433238T3/pl unknown
- 2017-03-22 BR BR112018069507-6A patent/BR112018069507A2/pt active Search and Examination
- 2017-03-22 MX MX2018011519A patent/MX384823B/es unknown
- 2017-03-22 AU AU2017238181A patent/AU2017238181B2/en active Active
- 2017-03-22 KR KR1020237034341A patent/KR20230147751A/ko not_active Ceased
- 2017-03-22 CN CN202210306552.XA patent/CN114716387B/zh active Active
- 2017-03-22 TR TR2018/13644A patent/TR201813644T1/tr unknown
- 2017-03-22 HU HUE17771028A patent/HUE055607T2/hu unknown
- 2017-03-22 ES ES21177643T patent/ES2972148T3/es active Active
- 2017-03-22 HR HRP20211386TT patent/HRP20211386T1/hr unknown
- 2017-03-22 EP EP17771028.2A patent/EP3433238B1/en active Active
- 2017-03-22 WO PCT/US2017/023508 patent/WO2017165473A1/en not_active Ceased
- 2017-03-22 CN CN201780031580.2A patent/CN109311827B/zh active Active
- 2017-03-22 ES ES17771028T patent/ES2877572T3/es active Active
-
2018
- 2018-09-21 CL CL2018002683A patent/CL2018002683A1/es unknown
- 2018-09-24 PH PH12018502048A patent/PH12018502048A1/en unknown
- 2018-09-25 SA SA518400103A patent/SA518400103B1/ar unknown
- 2018-09-25 ZA ZA2018/06389A patent/ZA201806389B/en unknown
-
2021
- 2021-09-13 CY CY20211100803T patent/CY1124487T1/el unknown
-
2022
- 2022-05-11 JP JP2022077992A patent/JP2022116028A/ja active Pending
- 2022-08-22 US US17/892,203 patent/US20230015736A1/en not_active Abandoned
-
2024
- 2024-01-11 JP JP2024002743A patent/JP2024050608A/ja active Pending
- 2024-12-13 US US18/979,841 patent/US20250195700A1/en active Pending
-
2025
- 2025-10-14 JP JP2025172559A patent/JP2026021351A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3925952T3 (da) | Prostataspecifik membranantigen-målrettede højaffinitetsmidler til endoradioterapi af prostatacancer / Prostate-Specific Membrane Antigen Targeted High-Affinity Agents For Endoradiotherapy Of Prostate Cancer | |
| DK3445767T3 (da) | Makrocykliske mcl1-inhibitorer til behandling af cancer | |
| EP3630733A4 (en) | HIGH AFFINITY AGENTS TARGETING A PROSTATE-SPECIFIC MEMBRANARY ANTIGEN FOR ENDORADIOTHERAPY IN PROSTATE CANCER | |
| DK3515937T3 (da) | Behandling af refraktorisk migræne | |
| EP3402517A4 (en) | Immunologic treatment of cancer | |
| DK3356385T3 (da) | 18f-taggede inhibitorer af prostataspecifik membranantigen (psma) og deres anvendelse til billededannelsesforbindelser til prostatakræft | |
| DK3288581T3 (da) | Fremgangsmåde til behandling af cancer | |
| DK3439635T3 (da) | Formuleringer til behandling af fast tumor | |
| DK4095130T3 (da) | Mærkede hæmmere af prostataspecifikt membranantigen (psma), deres anvendelse som billeddannelsesmidler og farmaceutiske midler til behandling af prostatacancer | |
| DK3189082T3 (da) | Anti-pd-l1-konjugater til behandling af tumorer | |
| DK3317394T3 (da) | Anordning til opformering af mikrovæv | |
| DK3622953T3 (da) | Kombinationsbehandling af cancer | |
| DK3448846T3 (da) | Syntese af indazoler | |
| DK3518932T3 (da) | Behandling af prostatacancer | |
| IL264443A (en) | Methods of treating prostate cancer | |
| DK3400072T3 (da) | Formuleringer til behandling af blærecancer | |
| DK3448849T3 (da) | Syntese af indazoler | |
| IL264589A (en) | Combination therapy for the treatment of pancreatic cancer | |
| DK3468604T3 (da) | Farmaceutiske kombinationer til behandling af cancer | |
| DK3638293T3 (da) | Sammensætninger til behandling af cancer | |
| DK3290436T3 (da) | Phenylalanin-fri protein til behandlingen af pku | |
| DK3464620T3 (da) | Bestemmelse af genetisk prædisponering for aggressiv prostatakræft | |
| HK1259764A1 (en) | Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer | |
| HK40028154A (en) | Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer | |
| DK3242132T3 (da) | Fremgangsmåder til detektering af cancer |